相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy
G. Sonpavde et al.
ANNALS OF ONCOLOGY (2010)
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
L. R. Molife et al.
ANNALS OF ONCOLOGY (2010)
Anti-Prostate-Specific Membrane Antigen-Based Radioimmunotherapy for Prostate Cancer
Scott T. Tagawa et al.
CANCER (2010)
Angiogenesis inhibitors in the treatment of prostate cancer
Paul G. Kluetz et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer
K. Anwer et al.
GENE THERAPY (2010)
Molecular Markers and Death From Prostate Cancer
John Concato et al.
ANNALS OF INTERNAL MEDICINE (2009)
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
C. N. Sternberg et al.
ANNALS OF ONCOLOGY (2009)
Phase II study of sunitinib in men with advanced prostate cancer
M. Dror Michaelson et al.
ANNALS OF ONCOLOGY (2009)
Current Perspectives in Prostate Cancer Vaccines
Philip M. Arlen et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2009)
Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors
Joseph Nariculam et al.
ASIAN JOURNAL OF ANDROLOGY (2009)
Phosphorylation of Bcl-2 and activation of caspase-3 via the c-Jun N-terminal kinase pathway in ursolic acid-induced DU145 cells apoptosis
Yu-xi Zhang et al.
BIOCHIMIE (2009)
p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer
Sak Kudahetti et al.
BJU INTERNATIONAL (2009)
Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics
Bo Dai et al.
BJU INTERNATIONAL (2009)
Targeting tumor angiogenesis with histone deacetylase inhibitors
Leigh Ellis et al.
CANCER LETTERS (2009)
Vascular Endothelial Growth Factor-C Protects Prostate Cancer Cells from Oxidative Stress by the Activation of Mammalian Target of Rapamycin Complex-2 and AKT-1
Michael H. Muders et al.
CANCER RESEARCH (2009)
An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer
Glenn Liu et al.
CLINICAL CANCER RESEARCH (2009)
Phase Ib dose-finding trial of intravenous (i.v.) panobinostat (PAN) with docetaxel (DOC) and prednisone (PRED) in patients (pts) with castration resistant prostate cancer (CRPC)
U. Vaishampayan et al.
EJC SUPPLEMENTS (2009)
Evaluation of lymph nodes with RECIST 1.1
L. H. Schwartz et al.
EUROPEAN JOURNAL OF CANCER (2009)
Therapeutic Vaccination with an Interleukin-2-Interferon-γ-Secreting Allogeneic Tumor Vaccine in Patients with Progressive Castration-Resistant Prostate Cancer: A Phase I/II Trial
Thomas H. Brill et al.
HUMAN GENE THERAPY (2009)
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Gerald L. Andriole et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Screening and Prostate-Cancer Mortality in a Randomized European Study
Fritz H. Schroeder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Effects of CXCR4 Antagonist CTCE-9908 on Prostate Tumor Growth
Stacy Porvasnik et al.
PROSTATE (2009)
Phase 1/2 dose-escalation study of a GM-CSF-Secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer
Celestial S. Higano et al.
CANCER (2008)
A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors
Nicola L. Steele et al.
CLINICAL CANCER RESEARCH (2008)
Pilot study of rapamycin in patients with hormone-refractory prostate cancer
Robert J. Amato et al.
CLINICAL GENITOURINARY CANCER (2008)
An open-label, multicenter, phase 1/2 study of AT-101 in combination with docetaxel and prednisone in men with hormone refractory prostate cancer
G. MacVicar et al.
EJC SUPPLEMENTS (2008)
Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study
Giuseppe Di Lorenzo et al.
EUROPEAN UROLOGY (2008)
Plasmid DNA- and messenger RNA-based anti-cancer vaccination
Benjamin Weide et al.
IMMUNOLOGY LETTERS (2008)
Phase I trial of the prostate-specific membrane antigen directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer
Matthew D. Galsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin
Anthony W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Treatment of Biochemical Recurrence of Prostate Cancer With Granulocyte-Macrophage Colony-Stimulating Factor Secreting, Allogeneic, Cellular Immunotherapy
Walter J. Urba et al.
JOURNAL OF UROLOGY (2008)
RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid
Todd M. Morgan et al.
PROSTATE (2008)
IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer
H. Wang et al.
CANCER GENE THERAPY (2007)
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases
Paul Mathew et al.
CLINICAL CANCER RESEARCH (2007)
YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts
Takahito Nakahara et al.
CANCER RESEARCH (2007)
Ursolic acid, a naturally occurring triterpenoid, demonstrates anticancer activity on human prostate cancer cells
E. Kassi et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2007)
Allogeneic retrovirally transduced, IL-2- and IFN-γ-secreting cancer cell vaccine in patients with hormone refractory prostate cancer -: a phase I clinical trial
T. H. Brill et al.
JOURNAL OF GENE MEDICINE (2007)
Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis
Martine Schmitz et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy
Gopal K. Bajaj et al.
UROLOGY (2007)
Clinical implications of neuroendocrine differentiation in prostate cancer
E. C. Nelson et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2007)
Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology, and end results (SEER) program
Matthew J. Hayat et al.
ONCOLOGIST (2007)
A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy
Amy M. Lin et al.
BJU INTERNATIONAL (2006)
Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy:: The GVAX™ vaccine for prostate cancer
Jonathan W. Simons et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2006)
Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins
Youyuan Xu et al.
CANCER RESEARCH (2006)
Expression of mTOR signaling pathway markers in prostate cancer progression
Celeste L. Kremer et al.
PROSTATE (2006)
Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer
JW Simons et al.
CLINICAL CANCER RESEARCH (2006)
Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature
EM Anderson et al.
CANCER GENE THERAPY (2006)
Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers
S Varghese et al.
CANCER GENE THERAPY (2006)
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer
PM Arlen et al.
CLINICAL CANCER RESEARCH (2006)
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer
PM Arlen et al.
JOURNAL OF UROLOGY (2005)
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer
NH Bander et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Molecular pathology of prostate cancer
C Hughes et al.
JOURNAL OF CLINICAL PATHOLOGY (2005)
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
WK Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer
AW Tolcher et al.
CLINICAL CANCER RESEARCH (2005)
Versatile prostate cancer treatment with inducible caspase and interleukin-12
EY Nikitina et al.
CANCER RESEARCH (2005)
Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts
LC Wu et al.
CANCER RESEARCH (2005)
PSA updated: Still relevant in the new millennium?
JB Shah et al.
EUROPEAN UROLOGY (2005)
Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease
A Berruti et al.
ENDOCRINE-RELATED CANCER (2005)
A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer
K Rao et al.
PROSTATE (2005)
Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors
B Sangro et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Survivin expression is associated with features of biologically aggressive prostate carcinoma
SF Shariat et al.
CANCER (2004)
Prostate-specific antigen:: A review of the validation of the most commonly used cancer biomarker
J Hernández et al.
CANCER (2004)
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: A modular phase I trial in androgen-independent prostate cancer
P Mathew et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer
GV Thomas et al.
CLINICAL CANCER RESEARCH (2004)
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer
MI Milowsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice
SJ Kim et al.
CANCER RESEARCH (2004)
A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer
MD Henry et al.
CANCER RESEARCH (2004)
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
PK Majumder et al.
NATURE MEDICINE (2004)
Molecular pathways to prostate cancer
ML Gonzalgo et al.
JOURNAL OF UROLOGY (2003)
Molecular biology of prostate cancer
WA Schulz et al.
MOLECULAR HUMAN REPRODUCTION (2003)
Screening for prostate cancer: An update of the evidence for the US Preventive Services Task Force
R Harris et al.
ANNALS OF INTERNAL MEDICINE (2002)
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
MS Kim et al.
NATURE MEDICINE (2001)
Peptide growth factors as biomarkers of prostate cancer risk
PH Gann et al.
EPIDEMIOLOGIC REVIEWS (2001)
Molecular genetics of prostate cancer
C Abate-Shen et al.
GENES & DEVELOPMENT (2000)
The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages
KL Talks et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
分享论文
